###### Strengths and limitations of this study

-   A mixed methods study design combines the strengths of both qualitative and quantitative approaches to understand the given problem.

-   The Nottingham Onset Schedule duration of untreated psychosis (DUP) version is a well-validated standardised instrument for assessing for the DUP.

-   This study also enrols caregivers who are crucial stakeholders in the assessment and mental healthcare of individuals with psychosis.

-   As with any cross-sectional study, this investigation is not designed to determine causality.

Introduction and background {#s1}
===========================

Psychotic disorders are among the leading contributors to adult mental illness and disease burden globally.[@R1] Psychotic disorders are profoundly disabling[@R4]---schizophrenia, the most prevalent psychotic disorder, was assigned the highest disability coefficient of all 235 conditions in the 2013 global burden of disease (GBD) study.[@R5] GBD disability weights range from 0 (perfect health) to 1 (death). GBD researchers assigned acute schizophrenia a disability weight of 0.778---more than three-quarters of the way towards death. Of note, the high GBD disability coefficient still captures only the disability experienced by the affected individual and not the impact of the illness on their close contacts or community.[@R6] This burden of psychotic disorders may be reduced by intervening early with antipsychotic medication especially at the first episode of psychosis (FEP).[@R7] There are, however, a disproportionately larger numbers of patients from sub-Saharan Africa (SSA) who are not on psychotropic medications or delay in receiving them.[@R8]

Duration of untreated psychosis (DUP) describes the period in the course of a psychotic illness between the onset of psychotic symptoms and initiation of antipsychotic medication at the FEP.[@R9] This delay, DUP, is crucial to psychosis research due to its ability to predict future outcomes.[@R9] Changes in brain structure and functioning develop much earlier before the onset of psychotic symptoms[@R11] and antipsychotic medication may slow this dysfunction leading to better outcomes.[@R12] Patients from SSA have been reported to have DUP of up to 5 years, compared with 1 year in high-income countries (HICs).[@R13] Shorter DUP of less than 2 years like that seen in HICs is associated with lower symptom severity, higher cognitive functioning, decreased substance use, less disability, better quality of life and better social functioning.[@R13] The prevalence and factors associated with long DUP in SSA have not been well described.[@R20]

In SSA, alternative and complementary therapies (ACTs) are commonly utilised in the initial treatment of psychotic disorders.[@R22] These ACTs encompass multiple health and wellness therapies that have not been part of conventional western medicine.[@R25] In Uganda, approximately 37% of patients with psychosis first seek care from ACTs such as faith healers, spiritual healers and traditional healers.[@R23] Instead of using antipsychotics, ACT practitioners typically use herbs, psychotherapy, psychodrama, symbolisms, rituals, spirituality and prayer to treat psychosis.[@R28] Often, these therapies are used exclusively during the onset of psychosis, which may delay initiation of treatment, leading to longer DUP and potentially worse outcomes.[@R29]

There is limited and inconsistent literature on what prolongs DUP in SSA---a research gap that hinders the development of effective interventions to reduce DUP.[@R20] There are regional variations in the choice of first contact for mental disorders including psychosis.[@R32] In a study in South Africa, for example, they reported that the first encounter was a general hospital[@R30] while in Uganda it is reported to be ACT.[@R24] There is also limited qualitative literature on the use of ACT and how it drives seeking of care and continued care for patients with psychotic disorders.[@R34] Given that families seek ACT for psychosis exclusively before biomedical care,[@R23] we hypothesise that the various factors primarily driven by previous use of ACT may be associated with delays in receiving antipsychotic medicine and therefore longer DUP. We undertake this study with the goal of describing the factors associated with long DUP as well as working collaboratively with ACT providers to improve early access to antipsychotic medications.

Aims and objectives {#s1a}
-------------------

We will conduct a mixed methods study design employing both quantitative and qualitative approaches concurrently. We aim to determine the prevalence and factors associated with a long DUP among patients with a FEP at Butabika hospital in Uganda. We also aim to document explanations for prior use of alternative and traditional therapies on DUP among patients with FEP presenting to Butabika hospital in Uganda.

Our conceptual framework will be based on Andersen's behavioural model of health service use[@R35] ([figure 1](#F1){ref-type="fig"}). Briefly, it postulates that predisposing, enabling, and need components in the population predict health behaviour and health outcomes. Predisposing population characteristics may include age, gender, stigma and socioeconomic status. Enabling population characteristics may include type of caregiver (family member vs non-family member), hospital access, availability of care and use of traditional healers. Need population characteristics are the actual or perceived factors that highlight someone needs the services. Need population may include substance use, cognitive function, quality of life and psychosis severity. These factors predict ACT use as a health behaviour which may mediate the DUP defined as the time to initiation of care at Butabika hospital.

![Conceptual framework based on Andersen's behavioural model of health service use showing predisposing enabling and need components.](bmjopen-2018-028029f01){#F1}

Methods {#s2}
=======

Study design and setting {#s2a}
------------------------

This mixed methods study will be based at the National Referral and Teaching psychiatric hospital at Butabika (Butabika hospital) ([figure 2](#F2){ref-type="fig"}). Using standardised tools, we will determine the DUP and the factors associated with it while concurrently exploring the role of previous ACT use on DUP.

![Entrance to Butabika hospital located at Kampala, Uganda.](bmjopen-2018-028029f02){#F2}

As a national referral institution, Butabika hospital is an ideal setting for the study of DUP among patients with FEP. As the main tertiary psychiatric institution, it is the final referral point for the whole country and therefore has a wide catchment area of patients from all regions in the country. Hospital records of the year 2018 reviewed in the primary study showed that 67% of all first contact patients at the hospital have a psychosis diagnosis. This provides an opportunity to gain insights into DUP across numerous Ugandan cultures. The hospital serves over 200 psychiatric outpatients per day and has six admitting wards and three convalescent wards that each admit up to 150 patients. In an initial study, we aimed to describe cognitive impairment among patients with a FEP at Butabika hospital.

Participants {#s2b}
------------

Participants will comprise those who agreed to be contacted for further studies as well as their caregivers. In the primary study, we recruited all patients presenting to Butabika hospital for the first time with a psychotic disorder. Among these participants, we then enrolled inpatients aged 18--60 years with a FEP without prior use of antipsychotic medication or less than 6 weeks of antipsychotic medication. In our original study, we used up to 6 weeks of continuous use of antipsychotic treatment to define the end of DUP.[@R36] This was based on literature that highlighted that remission occurred earlier in low-income and middle-income countries.[@R20]

Psychosis was confirmed using the Mini International Neuropsychiatric Inventory (MINI). Participants with HIV/AIDS and syphilis were excluded by serological testing. Substance-induced psychotic disorders were also excluded using the MINI. We collected information on sociodemographic characteristics, substance use history, quality of life, psychosis severity, previous childhood trauma and cognitive functioning. Cognitive functioning was assessed when the psychotic symptoms resolved. Participants who, in the original study, reported previous use of ACT were recorded as part of the initial research questions in the sociodemographic questionnaire.

All participants during the consent process were asked whether they can be contacted for further studies. All participants who agreed to be contacted for future studies will be our current study's target population. For the quantitative part of the study, by convenient sampling we will call back all participants who agreed to be contacted for future studies. For the qualitative part of the study, however, we will only purposefully sample a subsection of participants who reported previous use of ACT.

By the end of February 2019, the primary study had enrolled 173 participants. Approximately 30% of the enrolled participants have reported previous use of ACT. Only one participant had declined to be contacted for future studies.

Consent {#s2c}
-------

Participants who were previously enrolled in the primary study will be invited back together with a caregiver and asked further questions to guide this new study. Presenting to the hospital following the phone contact will not be taken as consent to participate in the study. Prospective participants will be invited to meet with study personnel in a private room for additional information on the study. A participant information sheet with the study details described will be provided in both Luganda and English (online [appendix 1](#SP1){ref-type="supplementary-material"}).
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The consent process will be carried out by a study psychiatric nurse. The patient will be allowed to read the information sheet and after to ask as many questions concerning the study before consenting to the study. The nurse will emphasise that enrolment is voluntary, and consent can be withdrawn at any stage. The nurse will inquire if the participant needs time to consider accepting to enter the study and if the patient asks for more time enrolment will be scheduled for another day. Before signing the consent form, the study nurse will ask prospective participants to repeat key points they have understood about the study in their own words. If they cannot accurately repeat at least three points, they will be declared unable to consent. A written informed consent will be signed after detailed explanation of the study purpose and thumb prints used in the event of difficulties in writing.

A similar consent process will be carried out for the caregivers who accompany the participants. Caregivers are the people who were listed as the next of kin in the initial study. As the initial study collected up to three next of kin, it will be up to the patient to decide who to come with as next of kin. This will be the individual that we shall consent to take part in the study. All consents and study documents will be in both English and Luganda translations. The participant and the caregiver will be given individual copies of the consent form to keep and a duplicate copy will be kept as a study record by the principal investigator. Consent forms will be stored under lock and key for 3 years as per ethical guidelines. Participants and caregivers who complete the consent process will then undergo eligibility screening.

Inclusion and exclusion criteria {#s2d}
--------------------------------

The inclusion criteria for the quantitative component of this study, therefore, are as follows: prior acceptance to be contacted for future studies and completion of initial data collection. We will exclude participants who are unable to provide informed consent. For the qualitative arm of the study, we will include participants who previously reported using ACT and have a caregiver willing to participate in the in-depth interviews. We will exclude participants who decline to have the interview audio-recorded.

Bias {#s2e}
----

### Non-response bias {#s2e1}

Participants from far off districts may not be willing to travel for the interviews. We will, however, inform them that they will be reimbursed for their time and transport.

### Recall bias {#s2e2}

Assessments for DUP by design are retrospective and thus may be prone to recall bias. It is not unusual to find participants unable to clearly define the onset of the psychotic episode due to the severity of the psychosis or cognitive impairment at psychosis onset which improves as the episode resolves.[@R39] As is required when using the Nottingham Onset Schedule-DUP (NOS-DUP), we will invite a close family member to corroborate the events surrounding the onset of the psychosis as is recommended when assessing DUP for patients with psychosis.[@R9] There are also some participants who when contacted may have a relapse of their psychotic illness and therefore will not be able to respond to the study questions.[@R32]

### Selection bias {#s2e3}

The fact that our original study is based on inpatients with a FEP implies that our sample may be prone to selection bias. However, the rates of previous ACT use in our sample are in keeping with previous literature in the same population.[@R40] Also, our objective may not primarily be a pathway to care but more specifically the effect of previous ACT use on initiating care and continuation with care.

Sample size {#s2f}
-----------

For the quantitative arm of the study, we used the Kish-Leslie formula[@R41] to estimate a sample size of 154 participants based on a 95% confidence limit, 50% hypothesised percentage of the outcome---initiation of care and an anticipated effect size of 0.4.[@R42] We used a hypothesised percentage of 50% given the limited literature on how many participants with FEP who initially utilise ACT go on to get care from hospitals. Allowing for a 20% non-response, we will recruit a minimum of 180 participants.

For the qualitative part of the study, we used a tool designed by Fugard and Potts to estimate sample sizes for qualitative data.[@R43] We estimated the most prevalent theme of previous use of ACT of 40% from previous studies.[@R40] We also anticipated that we will get 10 theme instances. We will therefore perform 30 in-depth interviews. In all, 15 in-depth interviews will involve patients and 15 in-depth interviews will involve caregivers of the selected participants. We estimate that this sample size will be enough to help us reach saturation.

Data collection {#s2g}
---------------

A summary of tools used in the study are listed in [table 1](#T1){ref-type="table"}. Interview questions will be loaded onto Open Data Kit V.2 (ODK2) using JavaScript software---an established data gathering tool, allowing for offline data entry with later upload to a secure online data server.

###### 

List of tools used in the study

  **Tool name:** variable(s) measured                                                                                                                                                     Brief notes
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Sociodemographic questionnaire:** age, gender, minimum education attained, household income and employment status                                                                     Using mapping abilities in Open Data Kit, we will be able to collect data on names of health facilities closest to the participants home to calculate distances to available services in the area.
  **Nottingham Onset Schedule-DUP version (NOS-DUP)** [@R48]: DUP                                                                                                                         Short, guided interview for recording several time points in the onset of psychosis. Onset is conceptualised as comprising a prodrome, emergence of positive psychotic symptoms and build-up of symptoms leading to a definite diagnosis (transition into psychosis). The NOS-DUP has been shown to have good validity in describing previous psychotic experiences with an intraclass correlation of 0.89 in some studies.[@R48]
  **Barriers to Accessing Care Evaluation (BACE)** [@R49]: barriers to accessing care                                                                                                     The BACE measures barriers to accessing medical care including antipsychotic treatment. It asks about 30 different barriers to care and has a special focus on stigma-related barriers. It has a 'treatment stigma' subscale to assess to what extent the stigma associated with mental healthcare has been a barrier for an individual. It has good psychometric properties and is also being used in studies in LMICs.[@R50]
  **Child Trauma Questionnaire (CTQ)** [@R55] **\*:** provides a brief method for screening of childhood traumatic experiences                                                            The CTQ is as 28-item questionnaire that takes 10--15 min to administer. It also includes a minimisation/denial scale for detecting individuals who may be under-reporting traumatic events. It has been used before in sub-Saharan Africa.[@R56]
  **The MINI International Neuropsychiatric Interview** [@R57] **\*:** psychosis diagnoses                                                                                                The MINI 7.0.2 is a semistructured interview guide for making Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) diagnoses. We administer module A (depressive disorder), module C (bipolar disorder), module I (alcohol use), module J (other substances) and module K (psychotic disorders).
  **Alcohol Smoking and Substance Use Involvement Test (ASSIST)** [@R58] **\*:** severity of substance use in the 3 months prior to enrolment                                             The ASSIST was developed for the WHO to detect and manage substance use and related problems in primary and general medical care settings. The ASSIST specifically collects information on nine major classes of substances that include tobacco, cannabis, alcohol, cocaine, amphetamines, inhalants, sedatives, hallucinogens and opioids. It also has a 10th category that collects any substance that might not fall in the nine general classes. The ASSIST is able to categorise different substance involvement into low, moderate and high risk. It has been previously used in our setting and in LMICs the reliability ranges from 0.81 to 0.95.[@R59]
  **Positive and Negative Signs and Symptoms of Schizophrenia (PANSS)** [@R60]\*: psychosis severity                                                                                      The PANSS is a 30-item clinician rated scale. It is used to determine resolution of positive psychotic symptoms before the assessment of cognitive function. Participants had to score less than 3 out of 7 in all domains to determine psychosis resolution.
  **WHO Quality of Life tool-Brief version (WHOQOL-BREF)** [@R61]\*: quality of life in four domains namely physical health, psychological health, social relationships and environment   Comprises 26 items. It is a shorter version of the original instrument that may be more convenient for use in large research studies or clinical trials. It has been previously used and validated in our setting.[@R62] It can be administered in approximately 10 min. In field trials, it was found to be reliable with Cronbach scores of 0.7.[@R63]
  **Neuroscreen** [@R64]\*:                                                                                                                                                               It is a collection of brief psychological screening tests administered via a smart phone application. It assesses six cognitive domains that include learning and memory, working memory, processing speed, motor speed and executive function. It has been validated for use in low- and middle-income settings. The tests in the battery are described elsewhere.[@R65] In specific populations, it has been found to have a sensitivity of 88.9% and sensitivity of 62.5%. The validity in first episode of psychosis will be described by the primary study.

\*Data were previously collected by primary study and provides independent variables in assessing the association between previous alternative and complementary therapy use and DUP.

DUP, duration of untreated psychosis; LMIC, low- and middle-income countries.

The sample for the quantitative component of the study will comprise a convenient sample from all formerly enrolled participants who agreed to be contacted for future studies. The study nurse will approach prospective participants to invite them to learn about the study and rule out a relapse of a psychotic episode. After signing the consent form, the study nurse will commence interviewing the participant using the standardised questionnaires of the NOS-DUP and Barriers to Accessing Care Evaluation (BACE).

For the qualitative component of the study, an interview guide will be developed and piloted that takes into consideration the contextual characteristics, individual characteristics, health behaviours and outcomes like quality of life according to our conceptual framework. Specifically, we will attempt to get an understanding on who made the decision to seek care from ACT initially as well as experiences and challenges while receiving ACT. We will also get a clearer understanding on experiences and challenges while using antipsychotic medication and preferred choices of treatment going forward.

We will purposefully sample from participants who reported previous use of ACT. In the original study, previous ACT use was described as use of a traditional healer/herbalist, use of a spiritual healer (like priests, pastors, sheiks) or use of traditional witch doctor. Among all the participants who reported previous ACT use, we will select five participants and five caregivers from each group to make our sample size. These will then be approached by the study nurse to obtain informed consent. We will then perform in-depth interviews using a standard guide. The interview for both patients and caregivers will entail face-to-face in-depth interviews. The interviews will be done individually with the patient alone and later the caregiver alone. The interviews will be held in a private research room provided by the hospital for the research study. The interview guide was developed by the research team based on input from literature[@R23] and preliminary results from the original study. The interview guide was piloted to ensure it captures all the required themes. The qualitative interview will be carried out by a clinical psychologist with previous expertise in carrying out qualitative studies among patients with severe mental illness.

Data analysis plan {#s2h}
------------------

For the quantitative analysis, the length of the DUP will be our dependent variable. A long DUP will be defined as more than 2 years before receiving antipsychotic medication after onset of psychotic symptoms.[@R9] We will use multivariate linear regression analyses to determine the association between ACT use with DUP while controlling for age and gender. For the qualitative objective, grounded theory approach will be used.[@R47] The goal of grounded theory approach is a theoretical analysis of how people resolve a major concern. A system of open-ended data evaluation that allows theory to merge from the dataset will guide data analysis. Interview material will be recorded in audio files, and then transcribed by the clinical psychologist. Coding will be done by the PI and the clinical psychologist to ensure we get similar themes. Data analysis will be done using Atlas software.

Data quality control {#s2i}
--------------------

In using standardised tools like the NOS-DUP version[@R48] and the BACE,[@R49] the authors hope to limit this bias. The NOS-DUP has been shown to have good validity in describing previous psychotic experiences with an intraclass correlation of 0.89 in some studies.[@R48] BACE has good psychometric properties and is also being used before in studies in low-income and middle-income countries.[@R50]

Both the NOS-DUP and the BACE will be translated from English to Luganda which is the the most common local language by two independent individuals from the local community with the goal of producing a translation that is appropriate for the lowest level of location education. The two translations will then be compared, and discrepancies resolved. Then, two additional individuals from the local community will back-translate from Luganda to English. Versions will be compared, and discrepancies will be resolved. After these translation procedures, the instrument will be pilot tested with at least five individuals' representative of the local respondent education level. Translations will be adjusted based on pilot participant understanding and feedback until the instrument can be read word-for-word and clearly understood by responders without any additional clarification.[@R52] The quality of the study will be further ensured through adequate training of interviewers (psychiatric clinical officer, medical officer and clinical psychologist), pre-testing and piloting the tools before use. ODK also allows for validation of data as it is being collected to prevent errors during data entry.

Patient and public involvement {#s2j}
------------------------------

The patients and public were involved indirectly in this study by agreeing to provide information for the primary study. Preliminary analyses from the primary study that showed a large percentage of patients use ACT informed the need for the current study. Information of this study will highlight if ACT use delays initiation of care and its overall effects on patient outcomes like cognitive function. This information will be shared with the administration of Butabika hospital who by law set the mental health policy agenda for the country.

Discussion {#s2k}
----------

Any intervention that seeks to improve outcomes in patients with psychosis needs to ensure that there is a short DUP.[@R21] Early, correct and sustained treatment with antipsychotic medication is essential to improved quality of life, recovery, cognitive and social functioning.[@R7] In Uganda, there is limited literature on the DUP and the factors associated. Also, previous literature has highlighted the use of ACT as an initial treatment choice for patients with psychosis.[@R24] It is essential to gain an understanding on the role of ACT on DUP. This can ensure that interventions are designed to ensure there is a reduction in DUP to ensure improved outcomes. Therefore, assessing for DUP and associated factors as well as qualitative research on the influence of ACT on DUP and care-seeking behaviour will be central to the proposed research.

Ethics and dissemination {#s2l}
------------------------

Ethical approval has been received from ethics committees at the school of medicine research and ethics committee of the college of health sciences at Makerere University (\#REC REF 2017--153) as well as the Uganda National Council of Science and Technology (HS237ES). All recruitment, consent and data collection assessments will be done in English or Luganda which is commonly spoken in the region. All recruitment and enrolment will be done after the normal routine care so as not to interfere with the clinic routine. Participants will be reimbursed \$6 (approximately sh20 000) for their time, either on completion of the full study assessment or when consent is withdrawn. Caregivers who participate in the qualitative study will also be paid \$6 (approximately sh20 000) separately from the patients they represent. No individual participant data will be reported in the published article. Participants found to be undergoing treatment seeking stigma will be referred to social workers and clinical psychologists for psycho education. We will also refer participants found to have a relapse of the psychotic illness to the clinic for management.

The results from this work will be shared with the management of Butabika hospital who are responsible for determining mental health policy in Uganda. We hope that this work will lead to evidence-based discussions on the need for early interventions to reduce DUP in Uganda. We will also publish our results in peer-reviewed journals. Our results will also be shared widely with the scientific world at conferences as oral or poster presentations.

Article summary {#s2m}
---------------

This is a research protocol of a mixed methods study that aims to determine the association between previous ACT use with DUP among patients with a FEP in Uganda.
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